In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from animal testing toward new approaches. One year later, much speculation ...
High-Frequency Oscillation vs Mechanical Ventilation for Neonatal Acute Respiratory Distress Syndrome 1. High-frequency ...
4d
NMR reveals site-specific structural signatures of therapeutic antibodies without isotope labeling
Monoclonal antibodies are widely used to treat diseases ranging from cancer to autoimmune disorders. The safety and efficacy of these biologic drugs depend on maintaining their correct ...
SEATTLE – February 17, 2026 – Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein-Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is ...
The FDA’s recent announcement to reduce, and in some cases replace, animal testing for monoclonal antibodies and other therapeutics represents one of the most consequential regulatory developments in ...
The FDA has released a draft guidance outlining how drug developers can validate new approach methodologies (NAMs) as alternatives to animal testing in preclinical drug developmen ...
Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility Bispecific antibodies (bsAbs) have emerged as a novel ...
On February 24, 2026, the Court in Case No. 1:23-cv-10861 (D. Mass.) granted Amgen’s motions for summary judgment of invalidity of the claims ...
A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...
Celldex Therapeutics (NASDAQ:CLDX) executives highlighted recent clinical progress and upcoming catalysts during a discussion at the Leerink Partners Global Healthcare Conference, with a major focus ...
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...
In this large international cohort of immunocompromised patients with ARF, we identified key risk and protective factors for mortality and intubation. These findings could improve outcomes by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results